| 000 | 01746 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513191401.0 | ||
| 264 | 0 | _c19990929 | |
| 008 | 199909s 0 0 eng d | ||
| 022 | _a1269-3286 | ||
| 024 | 7 |
_a10.1007/s00282-999-0105-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVávrová, J | |
| 245 | 0 | 0 |
_aEx vivo expansion CD34+/AC133+-selected autologous peripheral blood progenitor cells (PBPC) in high-risk breast cancer patients receiving intensive chemotherapy. _h[electronic resource] |
| 260 |
_bHematology and cell therapy _cJun 1999 |
||
| 300 |
_a105-12 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAC133 Antigen |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAntigens, CD |
| 650 | 0 | 4 |
_aAntigens, CD34 _xblood |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aCell Division _xdrug effects |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 |
_aEpirubicin _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlycoproteins _xblood |
| 650 | 0 | 4 |
_aHematopoietic Stem Cells _xcytology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 |
_aInterleukin-11 _xpharmacology |
| 650 | 0 | 4 |
_aInterleukin-3 _xpharmacology |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPeptides _xblood |
| 650 | 0 | 4 |
_aStem Cell Factor _xpharmacology |
| 700 | 1 | _aFilip, S | |
| 700 | 1 | _aVokurková, D | |
| 700 | 1 | _aBláha, M | |
| 700 | 1 | _aVanásek, J | |
| 700 | 1 | _aJebavý, L | |
| 773 | 0 |
_tHematology and cell therapy _gvol. 41 _gno. 3 _gp. 105-12 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00282-999-0105-8 _zAvailable from publisher's website |
| 999 |
_c10414062 _d10414062 |
||